Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by Guggenheim Capital LLC

Guggenheim Capital LLC decreased its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 31.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,235 shares of the company’s stock after selling 2,414 shares during the quarter. Guggenheim Capital LLC’s holdings in Medpace were worth $1,739,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. R Squared Ltd acquired a new stake in Medpace in the 4th quarter worth about $30,000. SBI Securities Co. Ltd. purchased a new position in shares of Medpace in the fourth quarter valued at approximately $31,000. Jones Financial Companies Lllp boosted its stake in shares of Medpace by 2,750.0% in the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company’s stock worth $38,000 after acquiring an additional 110 shares during the last quarter. Lindbrook Capital LLC increased its position in shares of Medpace by 27.6% during the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock worth $45,000 after purchasing an additional 29 shares in the last quarter. Finally, Assetmark Inc. raised its stake in Medpace by 20.1% in the 4th quarter. Assetmark Inc. now owns 173 shares of the company’s stock valued at $57,000 after purchasing an additional 29 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Leerink Partnrs raised shares of Medpace to a “hold” rating in a research note on Monday, March 24th. Mizuho lowered their price target on shares of Medpace from $400.00 to $355.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 9th. Truist Financial cut their price objective on shares of Medpace from $347.00 to $333.00 and set a “hold” rating for the company in a report on Thursday, April 10th. Robert W. Baird boosted their target price on Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a report on Monday, January 27th. Finally, TD Cowen cut Medpace from a “buy” rating to a “hold” rating and cut their price target for the company from $370.00 to $328.00 in a report on Monday, April 14th. Ten investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, Medpace has a consensus rating of “Hold” and a consensus target price of $357.50.

Medpace Stock Down 0.1 %

Shares of Medpace stock opened at $296.28 on Monday. The business’s fifty day simple moving average is $318.52 and its 200-day simple moving average is $333.25. The firm has a market cap of $8.96 billion, a PE ratio of 23.46, a price-to-earnings-growth ratio of 3.81 and a beta of 1.46. Medpace Holdings, Inc. has a 52 week low of $272.00 and a 52 week high of $459.77.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. As a group, equities analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.